Acapodene Toremifene: Phase III started

GTXI began the double-blind, placebo-controlled, U.S. Phase III PIN trial in 1,200 patients. Patients will receive either 20 mg toremifene or placebo. GTXI is seeking an SPA from FDA for the trial. GT...